Former Senior Vice President, Chief Scientific Officer and President of R&D · IRONWOOD PHARMACEUTICALS INC (IRWD)

Mark Currie

A named executive officer of IRONWOOD PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$4,132,134

Salary $125,000Stock awards $286,306

FY2018: $2,445,420

4th of 6 named executive officers at Ironwood Pharmaceuticals by FY2019 total.

6 named officers on file for IRONWOOD PHARMACEUTICALS, FY2019

Mark Currie’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 5 equity grants, each cited to its filing
  • IRWD’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how IRONWOOD PHARMACEUTICALS’s whole pay program stands against its peers

  • IRONWOOD PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IRWD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 21, 2020 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Mark Currie’s full pay file as a PDF — free

More than this page: up to 10 years of Mark’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Mark Currie compensation by year

IRONWOOD PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held
In US dollars, as IRONWOOD PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019
Salary$454,000$470,000$485,000$125,000
Bonus$0$0$0$0
Stock awards$0$0$231,360$286,306
Option awards$1,092,045$1,936,650$1,424,289$3,676,740
Non-equity incentive$301,000$210,000$242,500$0
Pension and deferred compensation$0$0$0$0
All other$8,040$8,040$62,271$44,088
Total$1,855,085$2,624,690$2,445,420$4,132,134

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IRONWOOD PHARMACEUTICALS INC DEF 14A filed April 21, 2020, accession 0001047469-20-002477, and prior-year filings. Open the filing on EDGAR.

How this page was built: the IRONWOOD PHARMACEUTICALS INC filed document, accession 0001047469-20-002477. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2020.

$1.9M
$2.6M
$2.4M
$4.1M
FY16
FY17
FY18
FY19
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
RSU22,706$302,217—
Option101,716—$16.02
Option420,110—$14.21
Option22,708—$17.20
Option4,447—$11.28
Option61,503—$18.47

Per the Outstanding Equity Awards at Fiscal Year-End table in IRONWOOD PHARMACEUTICALS INC's FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

4 Form 4 lines since the FY2019 proxy (filed April 21, 2020)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-16Grant or award—63,481$0.00676,900
2025-06-10Grant or award—45,000$0.00613,419
2024-06-18Grant or award—24,311$0.00568,419
2023-06-20Grant or award—22,350$0.00544,108

The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

IRONWOOD PHARMACEUTICALS’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Mark MallonFormer Chief Executive Officer$10,068,800
Peter HechtFormer Chief Executive Officer$6,159,489
Thomas McCourtPresident$5,104,326
Mark Currie · this pageFormer Senior Vice President, Chief Scientific Officer and President of R&D$4,132,134
Gina ConsylmanChief Financial Officer and Senior Vice President$3,453,579
Halley GilbertFormer Chief Administrative Officer and Senior Vice President, Corporate Development$3,434,859

Board service

IRONWOOD PHARMACEUTICALS board · FY2021–FY2025
Director compensation in US dollars, as IRONWOOD PHARMACEUTICALS reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$60,000$35,960—$0$95,960
FY2024$60,000$138,573—$0$198,573
FY2023$60,000$240,710—$0$300,710
FY2022$54,368$242,027—$0$296,395
FY2021$50,000$265,907——$315,907

Each year as the company reported it in IRONWOOD PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: IRONWOOD PHARMACEUTICALS pays directors a $50,000 cash retainer and $250,000 in RSAs. As stated in IRONWOOD PHARMACEUTICALS's FY2025 proxy.

Committees

Compensation

The full IRONWOOD PHARMACEUTICALS compensation record

free company brief

This page is one person within IRONWOOD PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the IRONWOOD PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IRONWOOD PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Currie's compensation dossier · One-time report. No refunds.